Revusiran
Amyloid Neuropathies, Familial
Alnylam Pharmaceuticalsnucleic_acidPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Amyloid Neuropathies, Familial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
fx-1006a Qilu Pharmaceutical Co., Ltd. | Phase 4 | A |
fx-1006a Pfizer | Phase 4 | BBB |
Tegsedi Akcea Therapeutics | Phase 4 | BB |
fx-1006a Qilu Pharmaceutical Co., Ltd. | Phase 4 | BB |
fx-1006a Pfizer | Phase 3 | BB |
View all 18 →
Same molecule, other indications
Revusiran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →